The in vitro inhibitory activity of rosamicin and erythromycin against 283 strains of nonfermenting, gram-negative bacilli was determined by using a broth dilution procedure. Rosamicin demonstrated greater activity than erythromycin against most strains tested. A number of species demonstrated significantly lower minimum inhibitory concentrations to rosamicin and would fall within the therapeutic range of the drug based on current pharmacological data.
The in vitro inhibitory activity of rosamicin and erythromycin against 283 strains of nonfermenting, gram-negative bacilli was determined by using a broth dilution procedure. Rosamicin demonstrated greater activity than erythromycin against most strains tested. A number of species demonstrated significantly lower minimum inhibitory concentrations to rosamicin and would fall within the therapeutic range of the drug based on current pharmacological data.
Rosamicin, a new macrolide antibiotic produced by Micromonospora rosaria, has been reported to be active against a variety of aerobic and facultative bacteria (2, 4, 8, 9) . Evidence also indicates activity against many anaerobic species, including Bacteroides fragilis (5) (6) (7) . In many reports the activity of rosamicin was found to be greater than that of erythromycin. The present study was undertaken to compare the in vitro activity of rosamicin with that of erythromycin against a large group of nonfermenting, gram-negative bacilli.
The following strains of bacteria isolated from clinical specimens were used in the study: 21 Pseudomonas aeruginosa, 15 P. maltophilia, 15 P. cepacia, 15 P. stutzeri, 16 P. putrefaciens, 16 P. putida, 15 P. fluorescens, 10 P. alcaligenes, 12 P. vesictuclaris, 12 P. acidovorans, 4 P. pseudoalcaligenes, 2 P. diminuta, 1 P. testosteroni, 20 Acinetobacter Iwoffi, 6 Alcaligenes faecalis, 13 A. odorans, 4 A. denitrificans, 14 Xanthomonas, 13 Moraxella nonliquefaciens, 11 Bordetella bronchicanis, 15 Achromobacter xylosoxidans, 16 Flavobacterium group II B, 6 VE-2 group, and 11 VE-1 group.
Standard reference powders of rosamicin and erythromycin were provided by Schering Corp., Bloomfield, N.J., and Eli Lilly and Co., Indianapolis, Ind., respectively.
The minimum inhibitory concentration (MIC) of each antibiotic was determined by using serial twofold microdilutions in Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.). Stock solutions of rosamicin and erythromycin were prepared and quality controlled by the tube dilution procedure by using organisms with known MICs. These strains included Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923, and P. aeruginosa ATCC 27853. Dilutions of antibiotics in broth were dispensed in 100-,ul volumes into plastic microdilution trays by using an MIC-2000 dispenser (Cooke Laboratory Products, Alexandria, Va.) and frozen at -70°C until use. Trays were quality controlled by using reference strains after initial preparation and again each time a group of plates was used. Reference MICs did not vary more than ±1 dilution interval during the study.
Organisms to be tested were grown in Trypticase soy broth, standardized turbidimnetrically, by using a Spectronic 88 (Bausch & Lomb, Inc., Rochester, N.Y.) at 640 nm and diluted to a final concentration in Mueller-Hinton broth. Trays were inoculated by using an MIC-2000 inoculator (Cooke Laboratory Products, Alexandria, Va.) to give a final concentration of approximately 105 colony-forming units per ml and incubated for 18 to 24 h at 35°C. Quality control of inoculum size was performed by pour plates.
The MIC end point was defined as the microdilution containing the lowest concentration of antibiotic showing no visible growth.
The activity of rosamicin and erythromycin against species of Pseudomonas is shown in Table 1 . With strains of P. aeruginosa, the activity of the two antibiotics was similar. MICs against all strains tested were >25 ILg/ml. With the majority of other Pseudomonas species, rosamicin was found to be at least fourfold more active than erythromycin. Rosamicin inhibited 70% of P. alcaligenes and 100% of P. putrefaciens at a concentration of 0.78 ,ug/ml, compared with 30 and 44%, respectively, inhibited by erythromycin. Rosamicin was likewise more active against strains of P. vesicularis, P. diminuta, P. acidovorans, and P. stutzeri.
The activity of the two antibiotics against a group of miscellaneous, nonfermenting, gramnegative bacilli is shown in Table 2 . Rosamicin again was found to be more active than erythromycin against most species tested. Rosamicin was distinctly more active than erythromycin against Xanthomonas species. Allbut one strain 2 indicate that rosamicin is more active than were inhibited by 0.78 ,ug or less of rosamicin per erythromycin against 24 , 1976 ). An upper therapeutic limit for rosamicin after a 250-mg oral dosage may therefore only be approximately 1 ,ug/ml (George Arcieri, Schering Corp., personal communication). Rosamicin, however, has been shown to attain higher levels in urethral and vaginal secretions of dogs and rats (3) as well as human prostatic tissue (1) . The drug may have value in the treatment of infections involving the urogenital tract. A recent study has shown rosamicin to be highly active against isolates of Neisseria gonorrhoeae, including penicillinase-producing strains (4). Although rosamicin was consistently more active than erythromycin against most organisms tested in the present study, the MICs against many strains still would not fall below the presently accepted upper limit of clinical susceptibility. The value of rosamicin in the treatment of infections involving nonfermenting, gram-negative bacilli must await fuirther study. This investigation was supported by a grant from the Schering Corp., Bloomfield, N.J.
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